Clinicians impressed with STRIDE findings The ACC.25 panelists on hand when Bonaca made his presentation were all clearly excited about these findings
In fact, you have to be dedicated to making lifestyle changes when taking semaglutide that support your weight loss efforts
However, ongoing research, such as the FLOW trial, which had been comparing GLP-1RAs to a placebo in patients with T2D and CKD, was recently halted prematurely due to their effectiveness
these ultimately result in improved glucose homeostasis and weight loss
But right now, unfortunately, it is unsustainable. The states biggest private insurer, Blue Cross Blue Shield of Massachusetts, also axed coverage of GLP-1 drugs for weight loss this year because the costs were driving up premiums for all members